Intercept Pharma (ICPT) received a Sell rating and a $25.00 price target from H.C. Wainwright analyst Ed Arce yesterday. The company’s shares closed last Tuesday at $28.12, close to its 52-week low of $23.78.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 17.1% and a 45.3% success rate. Arce covers the Healthcare sector, focusing on stocks such as Aurinia Pharmaceuticals, Paratek Pharmaceuticals, and Mirum Pharmaceuticals.
Intercept Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $54.50.
See today’s analyst top recommended stocks >>
Intercept Pharma’s market cap is currently $927.7M and has a P/E ratio of -3.20. The company has a Price to Book ratio of -7.90.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
